What podcasts say about Chloe Melley
Every statement, with the speaker, the exact quote and the moment it was said.
What Chloe Melley has said on podcasts
423 statements · 216 positive · 169 negative · 16 mixed · 22 neutral
Investors are increasingly cautious about large AI data-center financing deals
“investors being increasingly cautious about those huge financing deals”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 1:34
Constellation Brands’ outlook was viewed as overly cautious
“the outlook was seen as overly cautious”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 2:12
Consumer spending has not yet returned to healthy levels
“consumer spending is not back to healthy levels just yet”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 2:35
Intel’s CEO comments reassured investors about TerraFab involvement
“those comments from the CEO have reassured investors”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 3:10
Apple is entering the smart-home device market
“Apple is entering a brand new market for them, making smart home devices”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 3:48
Apple’s partnership model enables design control without full production costs
“it makes it easy for Apple to shape the design, shape the features without kind of shouldering the full cost of production”
Open the episode · SpaceX Funding; Constellation Brands Reports; Intel HigherListen at 4:17
Investors appear unfavorable toward C.H. Robinson’s planned RXO acquisition.
“So maybe investors not really liking this idea so much”
Open the episode · CH Robinson Sinks, Align Technology Drops on Antitrust Claim, DraftKings JumpsListen at 0:54
The trial results improve the vaccine’s path toward FDA approval.
“that now sort of paves the way for FDA approval”
Open the episode · Vaxcyte Surges, Harley Davidson Gains, CH Robinson Drops on News it Will Buy RXO for $5.8 BillionListen at 0:56
The trial results make Vaxcyte a leader in the pneumonia vaccine market.
“it makes this company a leader in this space”
Open the episode · Vaxcyte Surges, Harley Davidson Gains, CH Robinson Drops on News it Will Buy RXO for $5.8 BillionListen at 0:59
C.H. Robinson’s RXO acquisition is expected to close in the first half of next year.
“the deal expected to close in the first half of next year”
Open the episode · CH Robinson Sinks, Align Technology Drops on Antitrust Claim, DraftKings JumpsListen at 1:25
RXO shareholders are expected to own about 11% of the combined company.
“RXL shareholders are expected to own about 11% of the combined company”
Open the episode · CH Robinson Sinks, Align Technology Drops on Antitrust Claim, DraftKings JumpsListen at 1:29
Harley-Davidson’s lower-priced-bike strategy will pressure margins.
“That means some pressure on margins, of course, going forward”
Open the episode · Vaxcyte Surges, Harley Davidson Gains, CH Robinson Drops on News it Will Buy RXO for $5.8 BillionListen at 2:32
Align Technology has been dominant in the clear dental aligner market.
“Align has been in many ways dominating”
Open the episode · CH Robinson Sinks, Align Technology Drops on Antitrust Claim, DraftKings JumpsListen at 2:47
Potential legal overhangs make shareholders wary about Align Technology.
“when you think about any potential legal overhangs, you're going to see shareholders a bit wary of what this could mean for a company”
Open the episode · CH Robinson Sinks, Align Technology Drops on Antitrust Claim, DraftKings JumpsListen at 2:57
Arhaus is likely to return to profitability as marketing and customer expansion efforts increase.
“An analyst says it is likely to break back into the green as it ramps up its digital marketing and other efforts to expand its customer base.”
Open the episode · Novo Slides; Accenture Up; Arhaus UpgradeListen at 1:30
Novo Nordisk disappointed investors with its turnaround plans.
“Novo Nordisk. Disappointing investors here.”
Open the episode · Novo Slides; Accenture Up; Arhaus UpgradeListen at 2:22
Novo Nordisk quickly lost its GLP-1 market lead to Eli Lilly.
“it quickly lost its lead. to Eli Lilly.”
Open the episode · Novo Slides; Accenture Up; Arhaus UpgradeListen at 2:31
Airtel Money’s IPO is expected to raise about $800 million in London.
“the IPO of that business, of that unit, is now expected to raise about $800 million in London”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 2:23
The expected Airtel Money IPO size is below the previous $2 billion target.
“substantially lower than the previously targeted deal size of as much as $2 billion”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 2:30
Airtel Money could begin trading on the LSE in October.
“the business could be looking to start trading on the LSE in October”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 2:41
The reduced IPO size is disappointing for Airtel Africa.
“this reduced IPO size is quite disappointing for Etel Africa”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 2:46
The Airtel Money IPO could boost the London Stock Exchange.
“it could be actually quite a boost”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 3:12
Glencore was an important backer of Radiant World.
“Glencore was a very important backer of the company”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 4:03
Glencore accused Radiant World of fraud, while Radiant World sued Glencore.
“Glencore publicly accusing Radian World of fraud and Radian World suing Glencore”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 4:10
The Glencore–Radiant World situation will take considerable time to resolve.
“it's going to take quite a while to figure everything out that's happened behind the scenes”
Open the episode · Infineon Gains, Airtel Africa Dips, Glencore FallsListen at 4:16
Novartis needs to rebuild its drug-development pipeline
“it really does need to grow that pipeline again”
Open the episode · Stock Movers: Novartis, Soitec, Nordex (Podcast)Listen at 1:23
The DM1 drug’s success will be crucial to Novartis’s outlook
“the success of that drug will be key for the outlook”
Open the episode · Stock Movers: Novartis, Soitec, Nordex (Podcast)Listen at 2:03
Another Novartis trial disappointment could sharply hurt its shares
“another disappointment could, of course, weigh massively on the shares”
Open the episode · Stock Movers: Novartis, Soitec, Nordex (Podcast)Listen at 2:06
Nordex is emerging from a difficult period for the wind industry
“Nordex kind of emerging from a difficult period for the wind industry in general”
Open the episode · Stock Movers: Novartis, Soitec, Nordex (Podcast)Listen at 2:59
GPT-6 Astra’s launch is driving current AI optimism
“the main reason for this AI optimism today is the launch of OpenAI's GPT-6 Astra, this new model”
Open the episode · Stock Movers: Novartis, Soitec, Nordex (Podcast)Listen at 3:45
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.